Guided Therapeutics (GTHP) FCF Margin (2011 - 2025)
Guided Therapeutics (GTHP) reported FCF Margin of 49.32% for Q4 2025, up 3315068.0% on a YoY basis from N/an in Q4 2024, and up 89.32% sequentially from 461.67% in Q3 2025.
Guided Therapeutics (GTHP) FCF Margin (2011 - 2025) Analysis & Trends
Guided Therapeutics (GTHP) has 15 years of FCF Margin data on file, last reported at 49.32% in Q4 2025.
- For the quarter ending Q4 2025, FCF Margin rose 3315068.0% year-over-year to 49.32%; the trailing twelve-month figure through Dec 2025 stood at 139.24% (up 1584647.0% YoY), and the FY2025 full-year result was 139.5%, up 1584621.0% from the prior year.
- FCF Margin improved to 49.32% in Q4 2025, from 461.67% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 213.33% in Q4 2021 to a low of 34800.0% in Q2 2021.
- A 5-year average of 7834.01% and a median of 1967.42% in 2023 frame the typical range for FCF Margin.
- Across the five-year window, FCF Margin plunged 3215000 bps in 2024 and surged 3315068 bps in 2025, its largest moves.
- Tracing GTHP's FCF Margin over 5 years: stood at 213.33% in 2021, then sank by 9616 bps to 20300.0% in 2022, then soared by 95 bps to 1050.0% in 2023, then slumped by 3062 bps to 33200.0% in 2024, then soared by 100 bps to 49.32% in 2025.
- Business Quant data shows GTHP's FCF Margin at 49.32% in Q4 2025, 461.67% in Q3 2025, and 144.44% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 8.20% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 6.89% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 21.26% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 3.29% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -1.28% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 37.67% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 6.68% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 2.18% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Guided Therapeutics | 21.96 Mn | 21.89 Mn | 458,000.00 | -49.32% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -49.32% |
| Sep 30, 2025 | -461.67% |
| Jun 30, 2025 | -144.44% |
| Dec 31, 2024 | -33,200.00% |
| Mar 31, 2024 | -1,666.67% |
| Dec 31, 2023 | -1,050.00% |
| Jun 30, 2023 | -995.45% |
| Mar 31, 2023 | -2,268.18% |
| Sep 30, 2022 | -20,300.00% |
| Jun 30, 2022 | -7,320.00% |
| Mar 31, 2022 | -3,860.00% |
| Dec 31, 2021 | 213.33% |
| Sep 30, 2021 | -3,773.68% |
| Jun 30, 2021 | -34,800.00% |
| Dec 31, 2020 | -1,324.00% |
| Sep 30, 2020 | -764.94% |
| Dec 31, 2019 | -1,268.75% |
| Sep 30, 2019 | -22,800.00% |
| Jun 30, 2019 | -18,800.00% |
| Mar 31, 2019 | -1,033.33% |